0001140361-24-010237.txt : 20240228
0001140361-24-010237.hdr.sgml : 20240228
20240228210031
ACCESSION NUMBER: 0001140361-24-010237
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240226
FILED AS OF DATE: 20240228
DATE AS OF CHANGE: 20240228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ELMS STEVE
CENTRAL INDEX KEY: 0001250195
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36728
FILM NUMBER: 24698423
MAIL ADDRESS:
STREET 1: 888 SEVENTH AVE
STREET 2: 29TH FL
CITY: NEW YORK
STATE: NY
ZIP: 10106
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC.
CENTRAL INDEX KEY: 0001368514
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 562590442
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
BUSINESS PHONE: (201) 478-5552
MAIL ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
FORMER COMPANY:
FORMER CONFORMED NAME: R&R ACQUISITION VI, INC
DATE OF NAME CHANGE: 20060707
4
1
form4.xml
FORM 4
X0508
4
2024-02-26
0001368514
ADMA BIOLOGICS, INC.
ADMA
0001250195
ELMS STEVE
888 SEVENTH AVE
12TH FLOOR
NEW YORK
NY
10106
true
false
Common Stock
2024-02-26
4
A
0
24040
0
A
76441
D
Common Stock
3615671
I
See footnote
Stock Option (right to buy)
5.4
2024-02-26
4
A
0
37541
0
A
2034-03-26
Common Stock
37541
37541
D
These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.
Includes, as of the transaction date, (i) 24,040 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 25,815 RSUs granted on March 6, 2023, which will vest in full on March 6, 2024; and (iii) 26,586 shares of common stock owned by the reporting person.
These shares are owned by Aisling Capital II LP ("Aisling"). Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest thereon.
The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.
/s/ Steve Elms, by Brian Lenz as Attorney-in-fact
2024-02-28